11/7/2016. Antiretroviral Therapy Strategies. Learning Objectives. After attending this presentation, participants will be able to:
|
|
- Tobias Gallagher
- 6 years ago
- Views:
Transcription
1 Antiretroviral Therapy Strategies FORMATTED: 1/14/16 Joel E. Gallant, MD, MPH Medical Director of Specialty Services Southwest CARE Center Santa Fe, New Mexico Adjunct Professor of Medicine The Johns Hopkins University Baltimore, Maryland Financial Relationships With Commercial Entities Dr Gallant has served as a consultant or advisor to Bristol-Myers Squibb, Gilead Sciences, Inc, Janssen Therapeutics, Merck & Co, Inc, Theratechnologies, Inc, and ViiV Healthcare/GlaxoSmithKline. He has received research grants or contracts awarded to his institution from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Inc, Janssen Therapeutics, Inc, Merck & Co, Inc, Sangamo BioSciences, and ViiV Healthcare/ GlaxoSmithKline. (Updated 1/28/16) Slide 2 of 51 Learning Objectives After attending this presentation, participants will be able to: Describe current approaches to immediate or rapid initiation of antiretroviral therapy Discuss data supporting switching or simplifying therapy in patients whose viral loads are suppressed on ART. List the strengths and weaknesses of two-drug regimens and induction-maintenance strategies that have been studied to date in clinical trials. Slide 3 of 51 1
2 According to treatment guidelines which of the following is not a valid reason to switch therapy in a virologically suppressed patient? 2% 1. To simplify dosing 12% 22% 2% 62% 2. To eliminate food restrictions 3. To ensure the patient is on a recommended regimen 4. To prevent toxicity 5. None of the above. (All are valid reasons to switch) Slide 4 of 51 J.P. Slide 4 of 51 JP is a 28-yr-old, otherwise healthy graduate student, recently diagnosed with HIV infection Baseline labs: CD4 count 653 VL is 36, Genotype: wild-type virus Normal renal function, transaminases, lipids HBsAg, HCV negative His partner is HIV negative. They occasionally have sex with other partners. STD screening is negative He will start ART if you recommend it, and believes he will be adherent J.P. What would you start? Slide 6 of 51 % 1. EFV/FTC/TDF 5% 2. RPV/FTC/TDF 42% 3. EVG/c/TAF/FTC 26% 4. DTG/ABC/3TC 26% 5. DTG + FTC/TAF % 6. FTC/TAF + either DRV/c or DRV/r % % 7. Something else 8. I would defer therapy 2
3 DHHS Guidelines, July 216: What to Start Slide 6 of 51 Recommended regimens PI based DRV/r + (TDF/FTC or TAF/FTC) INSTI based RAL + (TDF/FTC or TAF/FTC) EVG/c/TDF/FTC or EVG/c/TAF/FTC DTG + (TDF/FTC or TAF/FTC) DTG/ABC/3TC Alternative regimens NNRTI based EFV/TDF/FTC or EFV + TAF/FTC RPV/TDF/FTC or RPV/TAF/FTC (VL <1,; CD4 >2) PI based (ATV/c or ATV/r) + (TDF/FTC or TAF/FTC) (DRV/c or DRV/r) + ABC/3TC DRV/c + (TDF/FTC or TAF/FTC) DHHS Guidelines for Antiretroviral Therapy in Adults and Adolescents, July 216. IAS USA Guidelines, July 216 What to Start Slide 7 of 51 Recommended Regimens DTG/ABC/3TC DTG + TAF/FTC EVG/c/TAF/FTC RAL + TAF/FTC Options When INSTIs are Not an Option DRV/c or DRV/r + (TAF/FTC, TDF/FTC or ABC/3TC) EFV/FTC/TDF RPV/FTC/(TAF or TDF) Günthard HF, et al. JAMA 216;316: T.F. Slide 9 of year-old gay man is diagnosed with HIV on a routine test He tested negative 1 year earlier. He was given antibiotics for a mono-like illness 6 months ago at an urgent care center He has been having condomless sex with multiple partners. He asked his doctor about PrEP and was told he should find a specialist. He sees a nurse and case manager the day after diagnosis, and baseline labs are drawn. He will see an HIV provider in 1 days. He is interested in starting ART. 3
4 Slide 1 of 51 T.F. When would you start ART? % 1. After he keeps several clinic appointments (~3 months) 17% 12% 1% 61% 2. After baseline genotype results are available (~2-3 wks) 3. At the HIV provider visit (1 days) 4. If creatinine is normal and HBsAg is negative (1-2 days) 5. Today RAPID Intervention Components Slide 11 of 51 Facilitation of same day appointments Flexible scheduling for providers (on-call back-up) ART regimens pre-approved for use prior to genotyping or lab testing Available as 5 day starter packs Accelerated process for health insurance initiation Recommendation for 1 st dose to be taken observed in the clinic Pilcher CD, et al. J Acquir Immune Defic Syndr 216 Engagement Timeline, SFGH Slide 12 of 51 Referral 1 st Clinic Visit 1 st PCP Visit ART Prescribed Viral load suppressed CD4-guided (26-9) Universal (21-3) RAPID 1 56 Pilcher CD, et al. J Acquir Immune Defic Syndr 216 4
5 Slide 13 of 51 T.F. The nurse calls in an HIV provider, who meets with patient briefly. ART is started immediately, with plans to follow up at scheduled visit in 1 days Which of the following regimens would you start? 7% 1. EVG/c/FTC/TAF 77% 2. DTG + FTC/TAF 1% 3. DTG/ABC/3TC 7% 4. DRV/c + FTC/TAF % 5. RPV/FTC/TAF % 6. EFV/FTC/TDF Rapid Start: Potential regimens Slide 14 of 51 Regimens to consider DTG + FTC/TAF EVG/c/FTC/TAF DRV/c + FTC/TAF Drugs to avoid ABC (need HLA B*571) TDF (need egfr) RPV (need VL, CD4) EFV, NVP (need genotype) D.F. Slide 15 of year-old man with HIV since 28. His nadir CD4 count was 362 and peak VL was 89,. Has been on EFV/TDF/FTC since diagnosis, with undetectable VL and a CD4 >5 2 years ago he declined switch to a newer regimen because he had no side effects other than vivid dreams, which he usually enjoyed, and he wanted a single-tablet regimen egfr consistently >6 Other medications: losartan 5 mg/d and atorvastatin 1 mg/d HLA B*571-negative 5
6 Slide 16 of 51 D.F. What do you recommend now? 37% 1. Make no changes 11% 2. Suggest switch to EFV + FTC/TAF 21% 3. Suggest switch to DTG/ABC/3TC 5% 4. Suggest switch to EVG/c/FTC/TAF 11% 5. Suggest switch to DTG + FTC/TAF 16% 6. Order bone density scan before deciding Switching therapy in suppressed patients: When and why? To manage side effects To manage or prevent drug toxicity To simplify regimen (number of doses or pills) To address food restrictions To address drug interactions To plan for pregnancy GS 189: Switch from F/TDF to F/TAF Weeks 48 and 96 Efficacy Virologic Outcome Treatment Difference (95% CI) FTC/TAF (n=333) FTC/TDF (n=33) FTC/TDF FTC/TAF Patients, % Wk Week Wk Success (< 5 copies/ml) Failure No Virologic Data FTC/TAF noninferior to FTC/TDF at Weeks 48 and 96 Raffi F, et al. HIV Glasgow, October 216, Glasgow, UK, Presentation O125 6
7 GS 1216: RPV/FTC/TDF to RPV/FTC/TAF Virologic Suppression at Week 48 (FDA snapshot) Virologic Outcome Treatment Difference, % (95% CI) RPV/FTC/TAF n=316 RPV/FTC/TDF n=313 Patients, % <1 Success Failure No Data n= Efficacy comparable across age, sex, geographic region No emergent resistance mutations detected in either group Orkin C, et al. HIV Glasgow 216, Glasgow, UK GS-116: EFV/FTC/TDF to RPV/FTC/TAF Virologic Suppression at Week 48 (FDA snapshot) Virologic Outcome Treatment Difference, % (95% CI) RPV/FTC/TAF n=438 EFV/FTC/TDF n=437 Patients, % Success Failure No Data n= Efficacy comparable across age, sex, geographic region No emergent resistance mutations detected in RPV/FTC/TAF group 1 pt in EFV/FTC/TDF group developed mutations (M184V, V16I/L, Y188L) Orkin C, et al. HIV Glasgow 216, Glasgow, UK 7 GS 189: Switch from F/TDF to F/TAF Change in Renal Biomarkers at Weeks 48 and 96 FTC/TAF FTC/TDF egfr Urine Protein:Cr Urine Albumin:Cr Urine RBP:Cr Urine β2m:cr Median Change, ml/min Median % Change All differences between treatments statistically significant (p <.1) Raffi F, et al. HIV Glasgow, October 216, Glasgow, UK, Presentation O125 7
8 GS 1216 and 116: Change in egfr at Week 48 Study 1216 Study 116 RPV/FTC/TAF RPV/FTC/TDF RPV/FTC/TAF EFV/FTC/TDF Median (Q1, Q3) Change egfr (ml/min)* p= p < Week Week Orkin C, et al. HIV Glasgow 216, Glasgow, UK GS 189: Switch from F/TDF to F/TAF: Bone density changes through Week 96 Spine Hip Mean % Change (95% CI) p < p < n Week Week FTC/TAF FTC/TDF FTC/TAF FTC/TDF p value FTC/TAF FTC/TDF p value 3% increase 4% 18% <.1 29% 11% <.1 3% decrease 8% 19% <.1 6% 15% <.1 Raffi F, et al. HIV Glasgow, October 216, Glasgow, UK, Presentation O125 GS 1216 and 116 Change in Spine BMD Through Week 48 Study 1216 Study 116 RPV/FTC/TAF RPV/FTC/TDF RPV/FTC/TAF EFV/FTC/TDF Mean % Change (95% CI) p <.1 p < BL Wk 24 Wk 48 BL Wk 24 Wk 48 (n=) (n=) (n=) (n=) RPV/FTC/TAF RPV/FTC/TDF RPV/FTC/TAF EFV/FTC/TDF 27% 11% 29% 13% 3% increase p<.1 p<.1 3% decrease 6% 13% p=.44 7% 14% p=.1 Orkin C, et al. HIV Glasgow 216, Glasgow, UK 8
9 TDF to TAF switch Slide 25 of 39 Advantages: Greater renal safety Improved bone density Smaller pill size Disadvantages: Loss of TDF lipid effect TAF will be more expensive than generic TDF IAS-USA recommendations: If there is no increase in the price of TAF vs. that of TDF, switching from TDF to TAF is reasonable even if patients are not experiencing TDF-related toxic effects. Günthard HF, et al. JAMA 216;316: D.F. Slide 25 of 51 Outcome: D.F. decided to make a switch based on the greater safety of TAF. He considered switching to FTC/TAF + EFV but decided that the dreams weren t always enjoyable, and ended up switching to EVG/c/FTC/TAF L.M. Slide 26 of year-old massage therapist taking DRV/c + FTC/TAF with VL <2 Previously failed EFV/TDF/FTC, which he had been taking 2-3 times per week. Has K13N mutation. He does not trust western medicine, he knows his body, believes he does not tolerate standard doses of most drugs, and feels he is experiencing a build-up of toxicity without any specific side effects He is not concerned about pill burden, as he takes dozens of supplements, but he has read about monotherapy, 2-drug regimens, and intermittent therapy, and would like to reduce the number of chemicals that he takes 9
10 Slide 28 of 51 L.M. How do you approach L.M.? 1% 1. Switch to 3TC plus either DRV/c or DTG 2. Switch to DTG or DRV/c monotherapy 2% 3. Switch to DTG + RPV 25% 4. Advise him to continue his regimen at full dose pending 35% more data % 5. Advise him to take his current regimen every other day 1% 6. Suggest chelation therapy to remove toxins Nuke-sparing and nuke-lite regimens Slide 29 of 51 Regimen Results DRV/r + RAL (ACTG ) Poor performance at high VL DRV/r + RAL (NEAT 2 ) Less effective at high VL, low CD4 DRV/r + MVC (MODERN 3 ) Less effective than standard ART ATV/r + RAL (HARNESS 4 switch) Less effective than standard ART LPV/r + RAL (PROGRESS 5 ) Small study; few pts with high VL LPV/r + EFV (ACTG ) Poorly tolerated but effective LPV/r + 3TC (GARDEL 7 ) As effective as standard ART LPV/r + 3TC or FTC (OLE 8 switch) As effective as standard ART ATV/r + 3TC (SALT 9 switch) As effective as standard ART DTG + 3TC (PADDLE 1 ) Promising but preliminary 1. Taiwo B, et al. AIDS. 211;25: Daar ES et al. Ann Intern Med Raffi et al. CROI 214, Abstract 84LB 7. Cahn P, et al. Lancet Infect Dis 214;14: Stellbrink H-J, et al. IAD 214. Abstract MOAB11 8. Gatell J, et al. AIDS 214. Abstract LBPE Van Lunzen J et al. IAC 214. Abstract A Perez-Molina, JA, et al. IAC 214. Abstract LBPE Reynes J, et al. AIDS Res Hum Retroviruses. 213;29: Figueroa MI, et al. EACS 215. Abstract 166. GARDEL: LPV/r + 3TC noninferior to LPV/r + 2 NRTIs at Wk 48 Slide 3 of 51 Patients (%) 4.6 (95% CI: -2.2 to 11.8; 1 P =.171) Dual ART (n = 214) Triple ART (n = 22) CD4 increase similar Grade 2-3 AEs more frequent in triple-art arm (88 vs 65 events) VF in 22 pts, of whom 2 had resistance (M184V) Both on dual ART n = Virologic Virologic D/C Due D/C for Success* Nonresponse Death Reasons to AE or Other *VL< 5 c/ml by FDA Snapshot algorithm. Cahn P, et al. Lancet Infect Dis 214;14:
11 PADDLE: All Pts Virologically Suppressed by Wk 8 of DTG + 3TC Included 4 pts with VL > 1, at BL HIV 1 RNA (copies/ml) Pt # Screen BL Day 2 Day 4 Day 7 Day 1 Wk2 Wk3 Wk4 Wk6 Wk8 Wk12 Wk , < 5 < 5 < 5 < 5 < 5 < 5 < , < 5 < 5 < 5 < 5 < 5 < 5 < 5 < 5 < , ,569 37, < 5 < 5 < 5 < 5 < , ,37 11, < 5 < 5 < 5 < 5 < ,362 2, < 5 < 5 < 5 < 5 < 5 < ,24 14, < 5 < 5 < 5 < 5 < 5 < 5 < 5 < ,64 18, < 5 < 5 < 5 < 5 < 5 < 5 < 5 < ,71 24, Not done < 5 < 5 < 5 < 5 < 5 < ,77 1,832 Not done < 5 < 5 < 5 < 5 < 5 < 5 < 5 < 5 1 1, < 5 < 5 < 5 < 5 < 5 < 5 < 5 < 5 < ,89 273,676 16,974 68, < 5 < 5 < ,58 64, < 5 < 5 < 5 < ,93 33,829 37,35 26, < 5 < 5 < 5 < 5 < 5 < ,348 15, < < 5 < 5 < 5 < ,185 23,5 15, < 5 < 5 < 5 Not done < 5 < 5 < , < 5 < 5 < 5 < 5 < 5 < 5 < 5 < ,1 25,828 11, < 5 < 5 < 5 < 5 < 5 < ,771 73,69 31, < 5 < 5 < 5 < 5 < 5 < ,83 16,32 35, < 5 < 5 < 5 < 5 < < 5 < 5 < 5 < 5 < 5 < 5 < 5 < 5 Figueroa MI, et al. EACS 215. Abstract 166. Slide 31 of 51 DTG Monotherapy Slide 36 of virologically suppressed patients in 4 observational studies at 4 centers switched to DTG monotherapy Virologic failure with emergence of integrase resistance occurred in 5 patients (4.4%) 4 had history of prior INSTI use, one with RAL failure. None had documented INSTI resistance Oldenbuettel C, et al. Antiviral Ther 216; Rojas J, et al. J Antimicrob Chemother 216 Jul;71: Katlama C, et al. J Antimicrob Chemother 216 Sep;71: Gubavu, C, et al. J Antimicrob Chemother 216;71: L.M. Slide 37 of 51 Outcome: L.M. agrees to remain on a 3-drug regimen for now, but asked to switch to DTG/ABC/3TC. He wants to switch to a 1- or 2-drug regimen once they are supported by stronger data 11
12 J.B. Slide 34 of year-old man who has been doing well for several years on TDF/FTC + DRV/r (6/1 mg bid) + RAL + ETR, with an HIV RNA <2 and CD4 763 He started ART in the late 8 s, and remembers taking AZT, d4t + 3TC, NVP, IDV and NFV, but there were others he doesn t remember. He knows he has some resistance. He has outlived two of his doctors, and attempts to obtain medical records from the survivors have been unsuccessful His younger friends are all on single-tablet regimens. He takes 9 pills per day and wants to switch to a once-daily regimen, with as few pills as possible (preferably one) J.B. What do you recommend? Slide 35 of 51 4% 1. EVG/COBI/FTC/TAF 1% 2. RPV/FTC/TAF 3. DTG/ABC/3TC 12% 4. EFV/TDF/FTC 1% 5. I would not recommend a single-tablet regimen, but I would simplify his 28% regimen in other ways 51% 6. I would order a proviral DNA genotype 1% 7. I would congratulate him on being alive and tell him to count his blessings and suck it up Switch studies in suppressed pts Trial From To Outcome + RAL EVG/COBI/FTC/TDF GS-123 TDF/FTC GS-264 TDF/FTC/EFV RPV/FTC/TDF Strategy-NNRTI TDF/FTC + NNRTI EVG/COBI/FTC/TDF Strategy-PI TDF/FTC + PI/r EVG/COBI/FTC/TDF SPIRIT 2 NRTI + PI/r RPV/FTC/TDF SPIRAL 2 NRTI + PI/r (exp d pts) 2 NRTI + RAL SALT ATV/r + 2 NRTI ATV/r + 3TC OLE LPV/r + 2 NRTIs LPV/r + 3TC GS-19 TDF-based ART EVG/COBI/FTC/TAF STRIIVING Suppressive ART DTG/ABC/3TC ATLAS-M ATV/r + 2 NRTIs ATV/r + 3TC GS-119 Salvage regimen EVG/COBI/FTC/TAF + DRV LATTE CAB or EFV + 2 NRTIs CAB + RPV (PO) GS-189 TDF/FTC + 3 rd agent TAF/FTC + 3 rd agent LATTE-2 CAB + ABC/3TC CAB + RPV (IM) GS-116 EFV/FTC/TAF RPV/FTC/TAF GS-1216 RPV/FTC/TDF RPV/FTC/TAF SWITHCMRK 2 NRTI + LPV/r (exp d pts) 2 NRTI + RAL HARNESS 2 NRTI + 3 rd Agent ATV/r + RAL Slide 36 of 51 12
13 SWITCHMRK: Prior failure predicts failure Slide 37 of 51 Inferior efficacy of RAL appeared driven by more failure among pts with previous virologic failure SWITCHMRK1 SWITCHMRK 2 Outcome RAL LPV/r (n = RAL LPV/r (n = (n = 174) 174) (n = 176) 178) Patients without previous virologic failure VL < 5 at Wk 24, % Treatment difference, % (95% CI) ) ) (-9.9 to (-8.5 to Patients with previous virologic failure VL < 5 at Wk 24, % Treatment difference, % (95% CI) to -2.5) to -2.6) (-33. (-26.5 Eron JJ, et al. Lancet. 21;375: Switching: Caveats Slide 38 of 51 Know the treatment and resistance history Avoid switching from high barrier to lower barrier agents when you don t Slide 39 of 51 Concordance with historical resistance (individual ARVs): 85% NNRTIs: 93% PIs: 84% NRTIs: 76% Identified major wild-type (nonmutant) variants at 97% False omission rate 3%. Toma J, et al. ICAAC 215, September 17-21, 215, San Diego. 13
14 Slide 4 of 51 J.B. GenoSure Archive results NRTI: 67N,184V, 219Q NNRTI: 13N PI: 1V, 54V, 63P, 71V, 77I, 82A, 9M INSTI: no mutations (DRV mutations: V11I, V32I, L33F, I47V, I5V, I54L, I54M, T74P, L76V, I84V, L89V) J.B. Slide 41 of 51 What do you recommend now? GS 119: E/C/F/TAF + DRV for treatmentexperienced patients Slide 48 of 51 Randomized (2:1), open-label (N=135) Eligibility: 4 mos <5 on ART containing DRV 2 prior failures 2-class resistance by historical genotype (inc. 3 TAMs and K65R) Historical genotype with no INSTI-R or currently on RAL No Q151M, T69ins, or DRV RAMS egfr >5 ml/min Week Primary Efficacy Endpoint 24 n=89 E/C/F/TAF + DRV 8 mg QD n=46 Baseline Regimen (BR) 48 E/C/F/TAF + DRV 8 mg QD 144 Objectives Primary Efficacy of E/C/F/TAF + DRV vs. BR at Week 24: FDA snapshot (<5) Secondary Safety and tolerability in both treatment arms over 24 and 48 weeks Efficacy at Week 48: VL <5 Efficacy at Week 48: VL <2 Huhn G, et al. IDWeek
15 GS 119: Baseline Characteristics Slide 49 of 51 %, unless otherwise indicated E/C/F/TAF + DRV Characteristics n=89 Baseline Regimen n=46 Median age, years Male Black (or African descent) Median CD4 count, cells/μl Median egfr CG, ml/min 99 1 DM / HTN / CVD / Hyperlipidemia 8 / 34 / 7 / / 37 / 4 / 28 Baseline Regimen Median No. pills per day pills per day 4 37 At least BID dosing TDF / ABC / other NRTIs 61 / 11 / / 11 / 13 RAL 56 5 Resistance 2-class / 3-class resistance 7 / / 2 M184V/I K65R 2 3 NNRTI-R / PI-R 89/ / 28 Huhn G, et al. IDWeek 215 GS 119: Virologic Outcome at Weeks 24 and 48* VL <5 Slide 5 of Week Week E/C/F/TAF + DRV (n=89) Baseline Regimen (n=46) Success Failure No Data Success Failure No Data Huhn G, et al. IDWeek 215 Proportional 5.3% (-3.4%, 17.4%) 18.3% (3.5%, 33.%) difference (95% CI) p=.23 p=.4 At Week 48, significantly higher virologic success rate at the more stringent cutoff (VL <2) with E/C/F/TAF + DRV compared with BR (9% vs 72%, p=.12) No participants in E/C/F/TAF + DRV developed resistance; 1 participant with viral rebound (Week 36) developed resistance in the BR arm (M184V+K65R) J.B. Slide 45 of 51 Outcome: JB was switched to a 2 pill once daily regimen of EVG/c/FTC/TAF + DRV. His VL remains suppressed and he likes his new regimen. 15
16 According to treatment guidelines which of the following is not a valid reason to switch therapy in a virologically suppressed patient? 1% 1. To simplify dosing % 54% 1% 43% 2. To eliminate food restrictions 3. To ensure the patient is on a recommended regimen 4. To prevent toxicity 5. None of the above. (All are valid reasons to switch) Slide 46 of 51 According to treatment guidelines which of the following is not a valid reason to switch therapy in a virologically suppressed patient? To simplify dosing 1% 2% To eliminate food restrictions % 12% To ensure the patient is on a recommended regimen 22% 54% To prevent toxicity 1% 2% None of the above. (All are valid reasons to switch) 43% 62% Slide 47 of 51 First Slide Second Slide Antiretroviral Therapy Strategies FORMATTED: 1/14/16 Joel E. Gallant, MD, MPH Medical Director of Specialty Services Southwest CARE Center Santa Fe, New Mexico Adjunct Professor of Medicine The Johns Hopkins University Baltimore, Maryland 16
Treating HIV: When the Guidelines Don t Fit. Joel Gallant, MD, MPH. Southwest CARE Center Santa Fe, New Mexico
Treating HIV: When the Guidelines Don t Fit Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, New Mexico Johns Hopkins University School of Medicine University of New Mexico School of Medicine Disclosures
More informationSwitching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor
More informationAntiretroviral Therapy in 2016
Antiretroviral Therapy in 2016 Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, NM University of New Mexico School of Medicine Johns Hopkins University School of Medicine Disclosures Consulting, Advisory
More informationCase 1 continued. Case 1 (cont) 12/8/16. MMAH Debate Panel Thursday, December 8, Case 1
MMAH Debate Panel Thursday, December 8, 2016 Case 1 HPI 55 yo man with newly diagnosed HIV initiates care in your clinic. His CD4+ cell count is 600, with HIV VL=90,000 copies/ml. He is asymptomatic at
More informationMore Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD
More Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD More Options, Some Opinions: Initial Therapies for HIV Judith S. Currier, MD University of California Los Angeles Los Angeles,
More informationState of the ART: Integrase Inhibitors Clinical Data. Juan Berenguer Hospital General Universitario Gregorio Marañón (IiSGM) Madrid, Spain
State of the ART: Integrase Inhibitors Clinical Data Juan Berenguer Hospital General Universitario Gregorio Marañón (IiSGM) Madrid, Spain Disclosures Consulting fees and honoraria Gilead, Janssen, MSD,
More informationCrafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Crafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary? Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical
More informationAre the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine
Are the current doses of ARV correct Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Can we lower doses of HIV meds safely? Consensus Panel in Alexandria
More informationHIV Treatment Update
HIV Treatment Update Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, NM Johns Hopkins University School of Medicine University of New Mexico School of Medicine Disclosures Consulting, Advisory Boards,
More informationHIV Treatment Update 8/3/2015. When to Start. Disclosures
8/3/215 HIV Treatment Update Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, NM University of New Mexico School of Medicine Johns Hopkins University School of Medicine Disclosures Consulting, Advisory
More informationReduced Drug Regimens
Dr. Jose R Arribas @jrarribas Financial disclosures JOSE R ARRIBAS Research Support: Speaker s Bureau: Viiv, Janssen, Abbvie, BMS, Gilead, MSD Board Member/Advisory Panel: Merck, Gilead Stock/Shareholder:
More informationTwo Drug Regimens Pros and Cons. Jürgen Rockstroh Department of Medicine I University Hospital Bonn, Bonn, Germany
Two Drug Regimens Pros and Cons Jürgen Rockstroh Department of Medicine I University Hospital Bonn, Bonn, Germany HIV Clinical Forum, Moscow, Russia, Friday 23 rd November 2018 Conflict of Interest: JKR
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationAntiretroviral Therapy: What to Start
FLOWED: 05-14-2015 Chicago, IL: May 18, 2015 Antiretroviral Therapy: What to Start Eric S. Daar, MD Professor of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles,
More informationClinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia
Clinical support for reduced drug regimens David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens First line optimisation Virological failure New
More informationHIV Treatment Update. Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London
HIV Treatment Update Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London Guidelines Nuke sparing Nukes Efavirenz placement as the gold standard ARV Role
More informationStarting and Switching ART: 2016
Starting and Switching ART: 2016 Luke Jerram Rajesh T. Gandhi, M.D. Massachusetts General Hospital Harvard Medical School Disclosures: grant support from EBSCO, Gilead, Merck, Viiv Thanks to Henry Sunpath,
More informationDrug toxicities: Safest PIs. Michelle Moorhouse 14 Apr 2016
Drug toxicities: Safest PIs Michelle Moorhouse 14 Apr 2016 Impact of PIs on AIDS mortality CDC.gov. Epidemiology of HIV infection. Evolution of PIs http://www.clinicaloptions.com/hiv/treatment%20updates/boosted%20pis/interactive%20virtual%20presentation/slideset.aspx
More informationRESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients
RESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients Kirsten White Gilead Sciences, Inc., Foster City, CA Background Bictegravir (BIC; B) is a novel, unboosted integrase strand
More informationThe Use of Integrase Inhibitors In Latin America: From Guidelines to the Real World Ernesto Martínez B., MD Internal Medicine, Infectious Diseases
De afbeelding kan niet worden weergegeven. The Use of Integrase Inhibitors In Latin America: From Guidelines to the Real World Ernesto Martínez B., MD Internal Medicine, Infectious Diseases DISCLOSURE
More informationARVs in Development: Where do they fit?
The picture can't be displayed. ARVs in Development: Where do they fit? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker
More information2-Drug regimens in HIV Anton Pozniak MD FRCP
2-Drug regimens in HIV Anton Pozniak MD FRCP Advantages Cost Dual Therapy Toxicities of Nukes CV risk, bone, renal disease Smaller STRs Keep drugs for later etc. Dual Therapy-Talking Points - What are
More informationDRUGS IN PIPELINE. Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015
DRUGS IN PIPELINE Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015 N(t)RTI The Development of TAF TAF Delivers the High Potency of TDF While Minimizing Off- Target Kidney and Bone Side Effects
More informationOptimizing Clinical Utility of Integrase Inhibitors. Anton Pozniak MD FRCP
Optimizing Clinical Utility of Integrase Inhibitors Anton Pozniak MD FRCP INSTIs-Characteristics Rapid viral load decline Low rates resistance/ Transmitted Resistance Less chance of side effects Less pills,
More informationVirological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo
Virological suppression and PIs Diego Ripamonti Malattie Infettive - Bergamo Ritonavir-boosted PIs Boosted PIs: 3 drugs in one The intrinsic antiretroviral activity Viral suppression and high baseline
More informationBon Usage des Antirétroviraux dans l Infection par le VIH
Bon Usage des Antirétroviraux dans l Infection par le VIH Pr. Jean-Michel Molina CHU St Louis, Assistance Publique Hôpitaux de Paris, INSERM U941 et Université Paris 7 Diderot, France 1 Liens d Intérêt
More informationDoes Resistance Still Matter? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Does Resistance Still Matter? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosure The speaker serves as a consultant to, and has received
More informationDidactic Series. CROI New Antiretroviral Therapies. Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016
Didactic Series CROI 2016 - New Antiretroviral Therapies Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016 This project is supported by the Health Resources and
More informationThe Integrase Inhibitor Drug Class: A Comparative Clinical Review
The Integrase Inhibitor Drug Class: A Comparative Clinical Review Ian Frank Professor of Medicine University of Pennsylvania Philadelphia, PA USA franki@pennmedicine.upenn.edu Disclosure Gilead, ViiV/GlaxoSmithKline:
More information2/16/2017. Management and Prevention of HIV Infection: Case Discussion. Case 1. Case 1
Management and Prevention of HIV Infection: Case Discussion Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA Grant
More informationARV Update: 2016 and Beyond Antonio E. Urbina, MD Associate Professor of Medicine Icahn School of Medicine Mount Sinai Hospital
ARV Update: 2016 and Beyond Antonio E. Urbina, MD Associate Professor of Medicine Icahn School of Medicine Mount Sinai Hospital Disclosures Scientific Advisory Panels: Gilead, Thera technologies, Merck,
More informationQué anuncian los nuevos trials?
Qué anuncian los nuevos trials? XVII Curso Nacional VIH/SIDA Sociedad Chilena de Infectología Agosto 2014 Dr. Carlos Beltrán Hospital Barros Luco Trudeau Universidad de Santiago Grupo SidaChile El presente
More informationWhat is the Virologic Support for Two-Drug Regimens?
What is the Virologic Support for Two-Drug Regimens? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker has received consulting
More informationUpdate on HIV Drug Resistance. Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Update on HIV Drug Resistance Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Learning Objectives Upon completion of this presentation, learners
More informationSwitching antiretroviral therapy to safer strategies based on integrase inhibitors. Pedro Cahn
Switching antiretroviral therapy to safer strategies based on integrase inhibitors Pedro Cahn Disclosures Research Grants: Abbvie-Merck-Richmond-ViiV Advisory boards: Merck-Sandoz-ViiV Switching in Virologically
More informationWhat is the magic number? Clinical perspective
What is the magic number? Clinical perspective Andrea De Luca Dipartimento Biotecnologie Mediche Università di Siena UOC Malattie Infettive AOU Senese Outline Regimens with reduced number of drugs Use
More informationHIV Update. On The Cutting Edge A Chronic Disease. Rhett M Shirley, MD
HIV Update On The Cutting Edge A Chronic Disease Rhett M Shirley, MD CDC Mid-point life expectancy estimates at age 20 years in three calendar periods, overall and by sociodemographic characteristics,
More informationHIV Update Allegra CPD Day Program Port Elizabeth Dr L E Nojoko
HIV Update 2014 Allegra CPD Day Program Port Elizabeth 12-02-2014 Dr L E Nojoko Global estimates for adults and children 2011 People living with HIV 34.0 million [31.4 million 35.9 million] New HIV infections
More informationHIV 101. Applications of Antiretroviral Therapy
HIV 101. Applications of Antiretroviral Therapy Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham Birmingham,
More informationINDUCTION/MAINTENANCE Clinical Case
INDUCTION/MAINTENANCE Clinical Case Dr. Jose R Arribas @jrarribas INDUCTION/MAINTENANCE (more or less) Dr. Jose R Arribas @jrarribas Disclosures Speaker s Bureau: Viiv, Janssen, Abbvie, BMS, Gilead, MSD
More informationNew treatment strategies: Novelties in ART & strategy
New treatment strategies: Novelties in ART & strategy Moderator: Josep Maria Llibre, Spain Pawel Jakubowski, Poland Chloé Orkin, UK NRTI reducing therapy: new strategies Professor Chloe Orkin Consultant
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More information2017 NSTC Annual Meeting Eric Daar April 18, 2017
Antiretroviral Therapy Update for TB Clinicians Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA Grants Consultant
More informationPanelists Melanie Thompson Jeffrey Lennox Wendy Armstrong Jonathan Li
Slide 1 of 51 Interactive ART Cases From the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University
More informationPotential Issues in Treating HIV/HCV co-infection with new HCV antivirals
State of the Art in Hepatitis C Virus Infection in HIV/HCV-Coinfected Patients FORMATTED: 11/17/15 David L. Wyles, MD Associate Professor of Medicine University of California San Diego San Diego, California
More informationDisclosures. Goals/Format. Patient 1 12/8/18. Antiretroviral Therapy Management. Harry Lampiris: None. Gabriel Chamie: None.
Disclosures Antiretroviral Therapy Management Panel Discussion & Debate Medical Management of AIDS & Hepatitis December 6, 2018 Harry Lampiris, MD, 1 Gabriel Chamie, MD, MPH 2 Susa Coffey, MD, 2 and Vivek
More informationDisclosures. Patient 1. Goals/Format 12/7/17. Antiretroviral Therapy Management:
Disclosures Antiretroviral Therapy Management: Panel Discussion & Debate Medical Management of AIDS & Hepatitis December 8, 2017 Brad Hare, MD, 1 Annie Luetkemeyer, MD 2 Susa Coffey, MD, 2 Vivek Jain,
More informationHIV - Therapy Principles
HIV - Therapy Principles Manuel Battegay and Christine Katlama Basel, Switzerland and Paris, France Disclosure MB has received honoraria for advisory board participation from Gilead, MSD, Pfizer, ViiV
More informationDisclosures (last 12 months)
HIV Research What s in the Pipeline? Samir K. Gupta, MD, MS Division of Infectious Diseases Indiana University School of Medicine Disclosures (last 12 months) Independent research grant funding by NIH/NHLBI,
More informationREASONS FOR DISCONTINUATION OF DUAL THERAPY WITH DOLUTEGRAVIR AND RILPIVIRINE
REASONS FOR DISCONTINUATION OF DUAL THERAPY WITH DOLUTEGRAVIR AND RILPIVIRINE R. Montejano, N. Stella-Ascariz, S. Garcia-Bujalance, JI. Bernardino, V. Hontañon, R. Mican, Montes M, E. Valencia, J. González,
More informationDr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa
Dr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa Transmitted drug resistance Resistance patterns in first-line failures in adults
More informationSimplifying Antiretroviral Therapy Regimens: It s not so simple
Simplifying Antiretroviral Therapy Regimens: It s not so simple Jonathan Colasanti, MD, MSPH Division of Infectious Diseases Emory University School of Medicine Disclosures No Financial Disclosures Parts
More informationDisclosures. Introduction to ARV Drug Resistance New Clinicians Workshop 12/9/16. Introduction. ARS Question
Disclosures Introduction to ARV Drug Resistance New Clinicians Workshop I have no disclosures Susa Coffey, MD Division of HIV, ID and Global Medicine ARS Question Which resistance test do you order for
More informationDisclosures. Introduction to ARV Drug Resistance New Clinicians Workshop. Introduction. ARS Question 12/6/2017
Disclosures Introduction to ARV Drug Resistance New Clinicians Workshop I have no disclosures Susa Coffey, MD Division of HIV, ID and Global Medicine ARS Question Which resistance test do you order for
More informationCROI 2018 Report Back
CROI 2018 Report Back Monika Roy, MD MAS Assistant Professor Division of HIV, Infectious Diseases, and Global Medicine bayareaaetc.org 1 Disclosures and Conflicts of Interest Nothing to report bayareaaetc.org
More informationDisclosures. Update on HIV Drug Therapy: A Case based Discussion. Case # 1: Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv
Disclosures Update on HIV Drug Therapy: A Case based Discussion Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv Philip Grant Assistant Professor Division of Infectious Diseases
More informationCase # 1. Case #1 (cont d)
Antiretroviral Therapy Management: Expert Panel Discussion George Beatty Susa Coffey Steve O Brien December 3, 2011 Moderated by Annie Luetkemeyer Case # 1 38 y.o. man, CD4 =350, VL=340K, new to your clinic
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals Are You Ready? New Drugs Are on the Way!
More information5/2/2016. Antiretroviral Therapy (ART) Strategies: A Case-Based, Panel Discussion
Antiretroviral Therapy (ART) Strategies: A Case-Based, Panel Discussion Joseph J. Eron, Jr, MD Professor of Medicine University of North Carolina at Chapel Hill Chapel Hill, North Carolina FORMATTED: 4/13/216
More informationDr Marta Boffito Chelsea and Westminster Hospital, London
Dr Marta Boffito Chelsea and Westminster Hospital, London Speaker Name Statement Dr Marta Boffito has received travel and research grants from and has been an advisor for Janssen, Roche, Pfizer, ViiV,
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationDebating view on less ART. Strategies under evaluation
Debating view on less ART Strategies under evaluation Andrea De Luca Dipartimento Biotecnologie Mediche Università di Siena Department of Infectious Diseases, Siena University Hospital, Italy Conflicts
More informationHistory (August 2010) Therapy for Experienced Patients. History (September 2010) History (November 2010) 12/2/11
(August 2010) Therapy for Experienced Patients Hiroyu Hatano, MD, MHS Assistant Professor of Medicine University of California San Francisco Medical Management of AIDS December 2011 42M HIV (CD4=450, VL=6250,
More informationTenofovir Alafenamide (TAF)
Frontier AIDS Education and Training Center Tenofovir Alafenamide (TAF) Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director, Frontier AETC ECHO January 28, 2016
More information4/14/2016. Breaking News From the 2016 Conference on Retroviruses and Opportunistic Infections
Breaking News From the 2016 Conference on Retroviruses and Opportunistic Infections Jeffrey L. Lennox, MD Professor of Medicine Associate Dean for Clinical Research Emory University School of Medicine
More informationCases from the Clinic(ians): Case-Based Panel Discussion
Cases from the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine The University of Alabama at Birmingham EDITED: 03-12-14 Learning Objectives After attending this presentation,
More informationDidactic Series. CROI 2014 Update. March 27, 2014
Didactic Series CROI 2014 Update Christian Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director,
More informationManagement of Treatment-Experienced Patients: New Agents and Rescue Strategies. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine
Management of Treatment-Experienced Patients: New Agents and Rescue Strategies Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine When to Modify Therapy! Studies to date show better responses
More informationAntiretroviral Drugs
Antiretroviral Drugs Dr Paddy Mallon UCD HIV Molecular Research Group Associate Dean for Research and Innovation UCD School of Medicine and Medical Science paddy.mallon@ucd.ie UCD School of Medicine &
More informationTreating HIV in 2018 Interactive Cases From the Clinic(ians)
Slide 1 of 51 Treating HIV in 2018 Interactive Cases From the Clinic(ians) Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama
More informationINTERGRASE INHIBITORS- WHAT S NEW?
INTERGRASE INHIBITORS- WHAT S NEW? Professor Margaret Johnson Royal Free London Foundation Trust October 2018 Targeting the HIV life-cycle NEW HIV VIRON MATURATION CO-RECEPTOR BINDING FUSION BUDDING CD4
More informationManagement of ART Failure. EACS Advanced HIV Course 2015 Dr Nicky Mackie
Management of ART Failure EACS Advanced HIV Course 2015 Dr Nicky Mackie Outline Defining treatment success Defining treatment failure Reasons for ART failure Management of ART failure Choice of second
More informationSimplified regimens: Pros and Cons
Rio de Janeiro, 2018 Simplified regimens: Pros and Cons Pedro Cahn Treatment Strategies: A long way Monotherapy Dual therapy STIs Triple therapy Non daily regimens Simplification Mega HAART Long Acting/Extended
More informationCROI 2017 Review: Novel ART Strategies
Mountain West AIDS Education and Training Center CROI 2017 Review: Novel ART Strategies Brian R. Wood, MD Assistant Professor of Medicine Medical Director, Mountain West AETC ECHO Telehealth March 2, 2017
More informationInvestigational Approaches to Antiretroviral Therapy
Investigational Approaches to Antiretroviral Therapy Rajesh T. Gandhi, MD Massachusetts General Hospital Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending
More informationTDF containing ART: Efficacy and Safety. Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia
TDF containing ART: Efficacy and Safety Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia 1 Indications Treatment of HIV-1 in combination with other antiretroviral
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationAntiretroviral Therapy: Panel Discussion
disclosures Antiretroviral Therapy: Panel Discussion Medical Management of HIV December 9, 217 Panelists: Harry Lampiris, MD; Annie Luetkemeyer, MD; Carina Marquez, MD Moderator: Oliver Bacon, MD none
More informationWhat are the most promising opportunities for dose optimisation?
What are the most promising opportunities for dose optimisation? Andrew Hill Liverpool University, UK Global Financial Crisis How can we afford to treat 15-30 million people with HIV in the future? Lowering
More informationTerapia del paciente naive con un régimen de Inhibidor de la proteasa Dr. Jose R Arribas IX Curso de avances en Infección VIH y hepatitis virales
Terapia del paciente naive con un régimen de Inhibidor de la proteasa Dr. Jose R Arribas IX Curso de avances en Infección VIH y hepatitis virales clinicaloptions.com/hiv Eficacia en Ensayos Clínicos pivotales
More informationInvestigational Approaches to Antiretroviral Therapy
Investigational Approaches to Antiretroviral Therapy Rajesh T. Gandhi, MD Massachusetts General Hospital Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending
More informationPrima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi
6 th INFECtivology TOday Paestum 15-16 -17 maggio 2014 Prima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi Istituto Nazionale per le Malattie
More informationAcquired INSTI Resistance. Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Acquired INSTI Resistance Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker has received consulting honoraria, speaker
More informationTreatment strategies for the developing world
David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia First line standard of care First line in the developing world First line failure
More informationReduced drug regimens
Reduced drug regimens Andrea De Luca MD Dipartimento di Biotecnologie Mediche, Università di Siena Department of Internal Medicine, University Hospital, Siena, Italy Conflicts of interest Research grants
More informationAntiretroviral Therapy: Current Recommendations, New Drugs, and Novel Strategies. Joel Gallant, MD, MPH Johns Hopkins University School of Medicine
Antiretroviral Therapy: Current Recommendations, New Drugs, and Novel Strategies Joel Gallant, MD, MPH Johns Hopkins University School of Medicine Initial Regimen: DHHS Guidelines 3/27/2012 Preferred Regimens
More informationDavid Cluck, PharmD, BCPS, AAHIVP Associate Professor of Pharmacy Practice Office 326 Phone
David Cluck, PharmD, BCPS, AAHIVP Associate Professor of Pharmacy Practice Office 326 Phone 423-439-6245 Email cluckd@etsu.edu Recall newly approved antiretrovirals and their respective place in therapy
More informationReduced drug regimens. Josep M Llibre Infectious Diseases & Fight AIDS Fndn Univ Hosp Germans Trias i Pujol Badalona, Barcelona
Reduced drug regimens Josep M Llibre Infectious Diseases & Fight AIDS Fndn Univ Hosp Germans Trias i Pujol Badalona, Barcelona jmllibre@flsida.org 9th IAS Conference on HIV Science (IAS 2017) 23 26 July
More informationSwitching antiretroviral therapy to safer strategies based on integrase inhibitors
Switching antiretroviral therapy to safer strategies based on integrase inhibitors Dr Paddy Mallon UCD HIV Molecular Research Group UCD School of Medicine paddy.mallon@ucd.ie UCD School of Medicine & Medical
More informationHow to best manage HIV patient?
How to best manage HIV patient? 1 2 Treatment Treatment Failure success HIV therapy = a long life therapy Why do we want to change a suppressive ART? Side effect Comorbidities Reduce drug burden How to
More informationAntiretroviral Therapy: Case-Based Panel Discussion
Antiretroviral Therapy: Case-Based Panel Discussion Rajesh T. Gandhi, MD Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending this presentation, learners
More informationPediatric HIV Update NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Pediatric HIV Update Christian B. Ramers, MD, MPH Assistant Medical Director, Family Health Centers of San Diego HIV/HCV Distance Education Specialist - NWAETC,
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationAntiretroviral Therapy in Joel Gallant, MD, MPH Johns Hopkins University School of Medicine
Antiretroviral Therapy in 2013 Joel Gallant, MD, MPH Johns Hopkins University School of Medicine When to Start When to Start: DHHS Guidelines, February 2013 ART recommended for all HIV+ individuals to
More informationKiat Ruxrungtham. Professor of Medicine Chulalongkorn University, and HIV-NAT, Thai Red Cross AIDS Research Centre
Kiat Ruxrungtham Professor of Medicine Chulalongkorn University, and HIV-NAT, Thai Red Cross AIDS Research Centre www.iasusa.org; www.aidsinfo.nih.gov; www.clinicaloptions.com; www.clinicaloptions.com/hiv
More informationWhat is the virological support for reduced drug regimens?
What is the virological support for reduced drug regimens? Pr Anne-Genevieve Marcelin Pitié-Salpêtrière Hospital UMR 1136 University Pierre et Marie Curie Paris, France Disclosure of Personal and Commercial
More informationComparison of Current International Guidelines for Treatment-Naive Pts
Comparison of Current International Guidelines for Treatment-Naive Pts Regimen DHHS [1] EACS [2] BHIVA [3] IAS-USA [4] GeSIDA [5] EFV/TDF/FTC RPV/TDF/FTC ATV/RTV + TDF/FTC DRV/RTV + TDF/FTC DTG/ABC/3TC
More informationProfessor Jeffery Lennox
BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions Professor Jeffery Lennox Emory University School of Medicine Atlanta, Georgia, USA 9-10 October 2014, Queen Elizabeth II Conference Centre,
More informationID Week 2016: HIV Update
Mountain West AIDS Education and Training Center ID Week 2016: HIV Update Robert Harrington, M.D. This presentation is intended for educational use only, and does not in any way constitute medical consultation
More information